GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PRA Health Sciences Inc (NAS:PRAH) » Definitions » PE Ratio without NRI

PRA Health Sciences (PRA Health Sciences) PE Ratio without NRI : 50.52 (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PRA Health Sciences PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-05-04), PRA Health Sciences's share price is $165.21. PRA Health Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was $3.27. Therefore, PRA Health Sciences's PE Ratio without NRI for today is 50.52.

During the past 9 years, PRA Health Sciences's highest PE Ratio without NRI was 444.71. The lowest was 19.56. And the median was 43.42.

PRA Health Sciences's EPS without NRI for the three months ended in Mar. 2021 was $0.86. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was $3.27.

As of today (2024-05-04), PRA Health Sciences's share price is $165.21. PRA Health Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $3.27. Therefore, PRA Health Sciences's PE Ratio for today is 50.52.

During the past years, PRA Health Sciences's highest PE Ratio was 484.62. The lowest was 19.56. And the median was 43.42.

PRA Health Sciences's EPS (Diluted) for the three months ended in Mar. 2021 was $0.86. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $3.27.

PRA Health Sciences's EPS (Basic) for the three months ended in Mar. 2021 was $0.89. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was $3.35.


PRA Health Sciences PE Ratio without NRI Historical Data

The historical data trend for PRA Health Sciences's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PRA Health Sciences PE Ratio without NRI Chart

PRA Health Sciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only 50.85 67.02 37.68 29.59 39.42

PRA Health Sciences Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.04 28.53 27.94 39.42 47.55

Competitive Comparison of PRA Health Sciences's PE Ratio without NRI

For the Diagnostics & Research subindustry, PRA Health Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PRA Health Sciences's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PRA Health Sciences's PE Ratio without NRI falls into.



PRA Health Sciences PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

PRA Health Sciences's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=165.21/3.270
=50.52

PRA Health Sciences's Share Price of today is $165.21.
PRA Health Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.27.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


PRA Health Sciences  (NAS:PRAH) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


PRA Health Sciences PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of PRA Health Sciences's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


PRA Health Sciences (PRA Health Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4130 ParkLake Avenue, Suite 400, Raleigh, NC, USA, 27612
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.
Executives
Michael J. Bonello officer: EVP & CFO 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Shannon Colin director, officer: President & CEO PRA INTERNATIONAL 12120 SUNSET HILLS ROAD, SUITE 600 RESTON VA 20190
Christopher L Gaenzle officer: EVP, CAO & General Counsel C/O INC RESEARCH HOLDINGS, INC., 3201 BEECHLEAF COURT, SUITE 600, RALEIGH NC 27604
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Alexander George Dickinson director 31542 CATALINA AVE LAGUNA BEACH CA 92651
Jeffrey T Barber director 6501 WESTON PARKWAY, SUITE 200 CARY NC 27513
Matthew P. Young director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
George R Roberts 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK CA 94025
Kkr Pra Investors Gp Ii Llc 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors L.p. 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors Gp Llc 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr North America Xi Ltd 10 percent owner KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Kkr North America Fund Xi L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001

PRA Health Sciences (PRA Health Sciences) Headlines

From GuruFocus

PRA Health Sciences to Report Second Quarter 2020 Earnings

By Marketwired Marketwired 07-02-2020

Pra Health Sciences Inc (PRAH) President & CEO Colin Shannon Sold $624,790 of Shares

By GuruFocus Research GuruFocus Editor 08-17-2020

PRA Health Sciences to Report Third Quarter 2020 Earnings

By GlobeNewswire GlobeNewswire 10-07-2020